Amylyx Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)
During thethree months ended June 30, 2025, no officers or directors of the Company (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(c) of Regulation S-K of the Exchange Act, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) except as described below:
Gina M. Mazzariello, our Chief Legal Officer and General Counsel, adopted a new Rule 10b5-1 trading plan on May 13, 2025, which is scheduled to expire on December 31, 2025. The aggregate number of shares of our common stock authorized to be sold under this new arrangement is 30,000, which includes shares that may be withheld or sold to cover withholding taxes at the time of vesting.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.